Suzuki 2015.

Methods	Randomised, double‐blind, placebo‐controlled trial (N = 208)
Participants	Patients with moderate‐to‐severely active UC
Interventions	Group 1: 5 mg/kg infliximab (n = 104) Group 2: placebo (n = 104) Patients received treatment at weeks 0, 2 and 6 Patients with a lower MCS at week 8 than at baseline were further treated with infliximab at weeks 14 and 22
Outcomes	Primary outcome: clinical response Secondary outcomes: clinical remission, mucosal healing, serum infliximab levels, adverse events
Notes	Reported in abstract form only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described beyond 'double‐blind'
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Unclear risk	Reported in abstract form only